Thomas T Dabrah

Title: Thomas T Dabrah: Innovator in Squalene Synthase Inhibition

Introduction

Thomas T Dabrah is a notable inventor based in New York, NY (US). He has made significant contributions to the field of biochemistry, particularly in the development of compounds that inhibit squalene synthase. His work is crucial in the treatment of fungal infections, showcasing the intersection of innovation and healthcare.

Latest Patents

Dabrah holds a patent for an "Inhibitor of squalene synthase." This patent involves the culture ATCC 74256 and its mutants, which are capable of producing zaragozic acid A and other squalene synthase inhibitors. The compound described in his patent is useful in treating fungal infections and inhibiting both squalene synthase and protein farnesyltransferase. He has 1 patent to his name.

Career Highlights

Currently, Thomas T Dabrah is associated with Pfizer Corporation, a leading pharmaceutical company. His role at Pfizer allows him to contribute to groundbreaking research and development in the pharmaceutical industry. His expertise in biochemistry and innovative thinking has positioned him as a valuable asset in his field.

Collaborations

Throughout his career, Dabrah has collaborated with esteemed colleagues, including Liang H Huang and Takushi Kaneko. These collaborations have fostered an environment of innovation and have led to advancements in their shared research interests.

Conclusion

Thomas T Dabrah's work in the field of squalene synthase inhibition exemplifies the impact of innovation in healthcare. His contributions continue to pave the way for new treatments and advancements in biochemistry.